|
WO2020221705A1
|
|
Novel process for preparing rhenium chelated mag3 oligonucleotides
|
|
WO2020212301A1
|
|
Novel process for preparing nucleotide p(v) monomers
|
|
WO2020173845A1
|
|
Oligonucleotide formulation method
|
|
WO2020169695A1
|
|
Phosphonoacetate gapmer oligonucleotides
|
|
WO2020169696A1
|
|
Novel phosphoramidites
|
|
WO2020104492A1
|
|
Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
|
|
WO2020043750A1
|
|
Neoantigen engineering using splice modulating compounds
|
|
WO2020038968A1
|
|
Microrna-134 biomarker
|
|
WO2020038976A1
|
|
Antisense oligonucleotides targeting usp8
|
|
WO2020038973A1
|
|
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038971A1
|
|
Antisense oligonucleotides targeting vcan
|
|
CA3105705A1
|
|
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
CA3098267A1
|
|
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
WO2020011869A2
|
|
Antisense oligonucleotides targeting tlr2
|
|
WO2020011745A2
|
|
Antisense oligonucleotides targeting cers6
|
|
WO2020011743A1
|
|
Antisense oligonucleotides targeting mafb
|
|
WO2020011744A2
|
|
Antisense oligonucleotides targeting cers5
|
|
WO2020011653A1
|
|
Antisense oligonucleotides targeting kynu
|
|
WO2020007889A1
|
|
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
|
|
Antisense oligonucleotides targeting mbtps1
|
